NASDAQ:TYRA Tyra Biosciences - TYRA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tyra Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $15.97 +0.12 (+0.76%) (As of 03/21/2023 12:00 AM ET) Add Compare Share Share Today's Range$15.50▼$16.0050-Day Range$7.12▼$15.9752-Week Range$4.93▼$16.00Volume82,593 shsAverage Volume55,800 shsMarket Capitalization$673.93 millionP/E RatioN/ADividend YieldN/APrice Target$20.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Tyra Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside25.2% Upside$20.00 Price TargetShort InterestBearish6.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$2.62 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.36) to ($1.61) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.54 out of 5 starsMedical Sector883rd out of 983 stocksPharmaceutical Preparations Industry426th out of 478 stocks 3.5 Analyst's Opinion Consensus RatingTyra Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.00, Tyra Biosciences has a forecasted upside of 25.2% from its current price of $15.97.Amount of Analyst CoverageTyra Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.18% of the float of Tyra Biosciences has been sold short.Short Interest Ratio / Days to CoverTyra Biosciences has a short interest ratio ("days to cover") of 24.2, which indicates bearish sentiment.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldTyra Biosciences does not currently pay a dividend.Dividend GrowthTyra Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TYRA. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Tyra Biosciences this week, compared to 0 articles on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tyra Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,620,000.00 in company stock.Percentage Held by Insiders19.50% of the stock of Tyra Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.60% of the stock of Tyra Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Tyra Biosciences are expected to decrease in the coming year, from ($1.36) to ($1.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tyra Biosciences is -12.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tyra Biosciences is -12.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTyra Biosciences has a P/B Ratio of 2.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Tyra Biosciences (NASDAQ:TYRA) StockTyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.Read More Receive TYRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address TYRA Stock News HeadlinesMarch 15, 2023 | americanbankingnews.comTyra Biosciences (NASDAQ:TYRA) Trading 13.1% Higher March 1, 2023 | finance.yahoo.comTyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into AchondroplasiaMarch 21, 2023 | Investing Daily (Ad)27 U.S. Cities Where Stocks Yield 26% a YearWhat’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. March 1, 2023 | finance.yahoo.comShould You Buy Tyra Biosciences (TYRA) Ahead of Earnings?January 3, 2023 | finance.yahoo.comTyra Biosciences, Inc. (TYRA) Stock Historical Prices & Data - Yahoo FinanceDecember 7, 2022 | finance.yahoo.comTyra Biosciences Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300November 24, 2022 | finance.yahoo.comHow Much Upside is Left in Tyra Biosciences, Inc. (TYRA)? Wall Street Analysts Think 184%November 10, 2022 | finance.yahoo.comTyra Biosciences to Present at Upcoming Investor ConferencesMarch 21, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastNovember 8, 2022 | finance.yahoo.comWall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 179%: Read This Before Placing a BetNovember 4, 2022 | finance.yahoo.comTyra Biosciences Reports Third Quarter 2022 Financial Results and HighlightsNovember 2, 2022 | finance.yahoo.comTyra Biosciences Announces Planned Chief Financial Officer TransitionOctober 31, 2022 | finance.yahoo.comWe Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business GrowthOctober 18, 2022 | uk.finance.yahoo.comTyra Biosciences, Inc. (TYRA)October 13, 2022 | finance.yahoo.comTyra Biosciences to Present Preclinical Data on TYRA-200, an FGFR1/2/3 Inhibitor, at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsSeptember 8, 2022 | finance.yahoo.comTyra Biosciences to Participate at September 2022 Investor ConferencesSeptember 5, 2022 | finance.yahoo.comTyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 CongressAugust 4, 2022 | finance.yahoo.comTyra Biosciences Reports Second Quarter 2022 Financial Results and HighlightsJuly 29, 2022 | investing.comHeart Test Laboratories Inc Unit (HSCS)June 23, 2022 | seekingalpha.comTyra Biosciences initiated with a Buy at H.C. WainwrightMay 24, 2022 | finance.yahoo.comHere's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn SituationMay 5, 2022 | finance.yahoo.comTyra Biosciences Reports First Quarter 2022 Financial Results and HighlightsApril 6, 2022 | finance.yahoo.comIntrahepatic Cholangiocarcinoma Clinical Trial Pipeline Shows Rapid Progress with 20+ Companies Working to Develop Therapies, Assesses DelveInsightMarch 8, 2022 | benzinga.comJefferies Upgrades Tyra Biosciences to Buy, Lowers Price Target to $27March 5, 2022 | seekingalpha.comTyra Biosciences GAAP EPS of -$0.24March 3, 2022 | finance.yahoo.comTyra Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and HighlightsFebruary 22, 2022 | finance.yahoo.comTyra Biosciences to Participate in Cowen 42nd Annual Healthcare ConferenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TYRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address TYRA Company Calendar Last Earnings11/02/2021Today3/21/2023Next Earnings (Estimated)3/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TYRA CUSIPN/A CIK1863127 Webwww.tyra.bio Phone619-728-4760FaxN/AEmployees25Year FoundedN/APrice Target and Rating Average Stock Price Forecast$20.00 High Stock Price Forecast$25.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+25.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,290,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-18.38% Return on Assets-17.92% Debt Debt-to-Equity RatioN/A Current Ratio48.73 Quick Ratio48.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.31 per share Price / Book2.18Miscellaneous Outstanding Shares42,200,000Free Float33,969,000Market Cap$673.93 million OptionableNot Optionable Beta0.83 Key ExecutivesDr. Todd Harris Ph.D. (Age 43)Pres, CEO, Sec., Treasurer & Director Comp: $612.72kDr. Ronald V. Swanson Ph.D. (Age 59)Chief Scientific Officer Comp: $536.19kDr. Hiroomi Tada M.D. (Age 58)Ph.D., Chief Medical Officer Comp: $519.65kMr. Daniel Bensen (Age 47)Co-Founder & COO Lynn SchermFin. DirectorMs. Esther van den Boom CPA (Age 42)CPA, Chief Financial Officer Dr. Robert L. Hudkins Ph.D. (Age 67)Chief Technology Officer Mr. Ali D. Fawaz J.D.Gen. Counsel & Sec.Ms. Sarah HonigVP of Corp. Devel. & StrategyDr. Piyush R. Patel Ph.D. (Age 57)Chief Devel. Officer More ExecutivesKey CompetitorsPhibro Animal HealthNASDAQ:PAHCAmarinNASDAQ:AMRNCTI BioPharmaNASDAQ:CTICRAPT TherapeuticsNASDAQ:RAPTAvadel PharmaceuticalsNASDAQ:AVDLView All CompetitorsInsiders & InstitutionsMorgan StanleySold 2,119 shares on 2/15/2023Ownership: 0.025%Geode Capital Management LLCBought 6,242 shares on 2/13/2023Ownership: 0.601%JPMorgan Chase & Co.Sold 20,340 shares on 2/13/2023Ownership: 0.472%Charles Schwab Investment Management Inc.Bought 2,328 shares on 2/13/2023Ownership: 0.233%Barclays PLCBought 3,025 shares on 2/13/2023Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions TYRA Stock - Frequently Asked Questions Should I buy or sell Tyra Biosciences stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tyra Biosciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TYRA shares. View TYRA analyst ratings or view top-rated stocks. What is Tyra Biosciences' stock price forecast for 2023? 2 brokerages have issued 1 year price targets for Tyra Biosciences' shares. Their TYRA share price forecasts range from $15.00 to $25.00. On average, they expect the company's share price to reach $20.00 in the next twelve months. This suggests a possible upside of 25.2% from the stock's current price. View analysts price targets for TYRA or view top-rated stocks among Wall Street analysts. How have TYRA shares performed in 2023? Tyra Biosciences' stock was trading at $7.60 on January 1st, 2023. Since then, TYRA shares have increased by 110.1% and is now trading at $15.97. View the best growth stocks for 2023 here. When is Tyra Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023. View our TYRA earnings forecast. How were Tyra Biosciences' earnings last quarter? Tyra Biosciences, Inc. (NASDAQ:TYRA) released its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.39) by $0.33. When did Tyra Biosciences IPO? (TYRA) raised $100 million in an initial public offering on Wednesday, September 15th 2021. The company issued 6,700,000 shares at $14.00-$16.00 per share. What is Tyra Biosciences' stock symbol? Tyra Biosciences trades on the NASDAQ under the ticker symbol "TYRA." Who are Tyra Biosciences' major shareholders? Tyra Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.60%), JPMorgan Chase & Co. (0.47%), Charles Schwab Investment Management Inc. (0.23%), Bank of America Corp DE (0.05%), Morgan Stanley (0.02%) and UBS Group AG (0.01%). Insiders that own company stock include Boxer Capital, Llc and Mva Investors, Llc. View institutional ownership trends. How do I buy shares of Tyra Biosciences? Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Tyra Biosciences' stock price today? One share of TYRA stock can currently be purchased for approximately $15.97. How much money does Tyra Biosciences make? Tyra Biosciences (NASDAQ:TYRA) has a market capitalization of $673.93 million. The company earns $-26,290,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. How can I contact Tyra Biosciences? Tyra Biosciences' mailing address is 2656 STATE STREET, CARLSBAD CA, 92008. The official website for the company is www.tyra.bio. The company can be reached via phone at 619-728-4760 or via email at aconrad@tyra.bio.. This page (NASDAQ:TYRA) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.